Astria Therapeutics (NASDAQ:ATXS) Stock Crosses Below 50 Day Moving Average – Here’s Why

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $8.26 and traded as low as $6.99. Astria Therapeutics shares last traded at $7.06, with a volume of 204,454 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a research report on Thursday, January 23rd. Oppenheimer raised their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. Finally, JMP Securities assumed coverage on Astria Therapeutics in a research report on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price on the stock. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $25.67.

Astria Therapeutics Stock Up 0.1 %

The firm has a 50 day moving average of $8.13 and a 200 day moving average of $10.05. The firm has a market cap of $395.01 million, a price-to-earnings ratio of -3.35 and a beta of 0.67.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new position in shares of Astria Therapeutics in the fourth quarter valued at $41,000. Tower Research Capital LLC TRC boosted its position in Astria Therapeutics by 109.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Astria Therapeutics in the fourth quarter worth $50,000. Virtus ETF Advisers LLC bought a new position in Astria Therapeutics during the fourth quarter valued at about $65,000. Finally, Quest Partners LLC increased its position in Astria Therapeutics by 180.8% in the third quarter. Quest Partners LLC now owns 9,004 shares of the biotechnology company’s stock worth $99,000 after buying an additional 5,798 shares during the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.